Aim This study was carried out to assess the minimal residual disease in Tunisian patients
with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors in routine clinical …

The efficacy of imatinib mesylate has been demonstrated in patients with chronic phase of
chronic myeloid leukemia (CML) as well as in advanced phase disease. The aim of this …

Tyrosine kinase inhibitors (TKIs) active against BCR-ABL have become integral to the
treatment of chronic myelogenous leukemia (CML) and are particularly effective in patients …

We evaluated responses to the treatment and long‐term outcomes of chronic myeloid
leukemia patients treated with imatinib as first‐line treatment in routine clinical setting from …

Chronic myeloid leukemia (CML) is a malignant clonal blood disease that originates from a
pluripotent hematopoietic stem cell. The cytogenetic hallmark of CML, the Philadelphia …

The widespread introduction of tyrosine kinase inhibitor (TKI) therapy has radically changed
the treatment strategy and goals of treatment of chronic myeloid leukemia (CML). In the past …

Patients with chronic myeloid leukemia who fail to achieve timely treatment responses have
a worse prognosis. Although many patients respond well to first-line treatment with imatinib …

RESUMO O tratamento da leucemia mieloide crônica (LMC) foi radicalmente modificado
com a introdução dos inibidores de tirosina quinase (ITK) na prática clínica. Entretanto, a …

More sensitive techniques are required for the detection of low frequencies of malignant
cells during and after treatment, ie, detection of minimal residual disease (MRD). In order to …

More than 80% of newly diagnosed patients with chronic myeloid leukemia in chronic phase
will achieve a complete cytogenetic response (CCR) with the standard dose of 400 mg …